Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

Expert Opinion on Drug Metabolism & Toxicology
André J Scheen

Abstract

Patients with type 2 diabetes (T2DM) are exposed to a high risk of cardiovascular disease (CVD) requiring a global therapeutic approach. Statin therapy has proven its efficacy in reducing CVD events in T2DM patients. Dipeptidylpeptidase-4 inhibitors (gliptins), which are increasingly used to target hyperglycemia, also offer promising preliminary results regarding a possible reduction in CVD events. As most patients with T2DM may be treated with both a statin and a gliptin, dual pharmacological therapy, possibly as a fixed-dose combination (FDC), deserves further consideration. The reader is provided with an update of information on the pharmacokinetics (PK) and pharmacodynamics (PD) of atorvastatin and sitagliptin . The article provides an analysis of the potential PK/PD interactions between the two compounds and puts into perspective the potential cardiovascular protection that such a dual therapy may offer in patients with T2DM. Atorvastatin and sitagliptin are not prone to PK drug-drug interactions. Their coadministration, either separately or in an FDC, improves both blood glucose levels and cholesterol concentrations, without clinically relevant adverse events. The atorvastatin plus sitagliptin combination may be used to r...Continue Reading

References

Mar 7, 2001·Diabetes, Obesity & Metabolism·M R BurgeD S Schade
Nov 21, 2001·Cardiovascular Drugs and Therapy·F BerniniR Paoletti
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Oct 9, 2003·Clinical Pharmacokinetics·Hans Lennernäs
Apr 28, 2004·Diabetes Care·Joyce A Cramer
Oct 27, 2004·Archives of Internal Medicine·Antonio CerielloJaakko Tuomilehto
May 25, 2005·Journal of Internal Medicine·B H R WolffenbuttelUNKNOWN Dutch Corall Study Group
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Sander I van Leuven, John J P Kastelein
Jun 21, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Aug 22, 2006·Journal of Clinical Pharmacology·Menger ChungCandace Bramson
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Jan 16, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stella H VincentGary A Herman
Mar 14, 2007·Drugs·Katherine A Lyseng-Williamson
Jun 19, 2007·Biopharmaceutics & Drug Disposition·Arthur BergmanRajesh Krishna
Jun 4, 2008·Diabetes, Obesity & Metabolism·J C N ChanD Williams-Herman
Nov 13, 2008·Diabetologia·R R HolmanUNKNOWN Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group
Dec 3, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·D P KaoJ Kugler
Jan 30, 2009·Diabetes, Obesity & Metabolism·C J Bailey, C Day
Feb 11, 2009·Journal of Clinical Pharmacology·Arthur J BergmanGary A Herman
Feb 25, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·B J Boucher
Mar 3, 2009·Pharmacotherapy·Robert V DiGregorio, Yanina Pasikhova
Jun 12, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Nov 17, 2009·Diabetes Research and Clinical Practice·William L BakerCraig I Coleman
Mar 20, 2010·Journal of the American College of Cardiology·Kwang Kon KohEak Kyun Shin
Apr 24, 2010·International Journal of Clinical Practice·S S EngelB J Goldstein
May 29, 2010·Current Vascular Pharmacology·Michael S KostapanosMoses S Elisaf
Jun 18, 2010·Expert Opinion on Drug Safety·Vasilios G AthyrosDimitri P Mikhailidis
Jul 2, 2010·Diabetes, Obesity & Metabolism·A J Scheen
Aug 10, 2010·Clinical Pharmacokinetics·André J Scheen
Aug 17, 2010·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Dec 7, 2010·Atherosclerosis·Kwang Kon KohMichael J Quon
Jan 6, 2011·Diabetes, Obesity & Metabolism·P AnagnostisD P Mikhailidis

❮ Previous
Next ❯

Citations

Feb 15, 2013·European Journal of Clinical Pharmacology·Christina L AquilanteJulie A Predhomme
May 6, 2015·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Dec 10, 2014·Expert Opinion on Drug Safety·Sri Harsha Tella, Marc S Rendell
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Jan 1, 2013·Journal of Drug Assessment·Niki KatsikiAsterios Karagiannis
Jul 15, 2017·Journal of General Internal Medicine·Rupinder Singh ButtarMichal L Melamed

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Diabetic Medicine : a Journal of the British Diabetic Association
R Bhome, H Penn
Expert Opinion on Pharmacotherapy
Sreevidya Subbarayan, Mark Kipnes
Expert Opinion on Pharmacotherapy
André J Scheen
© 2021 Meta ULC. All rights reserved